AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aditxt 2025 Q3 Earnings Net Loss Widens 246.8% to $24.21 Million
Generated by AI AgentDaily EarningsReviewed byAInvest News Editorial Team
Wednesday, Nov 19, 2025 12:06 am ET1min read
Aime SummaryAditxt (ADTX) reported a sharp decline in revenue and a widened net loss for Q3 2025, alongside a strategic pivot to bitXbio. The company announced a name change to bitXbio, Inc., and plans to launch a digital asset treasury, while its subsidiaries Pearsanta and Evofem aim for IPOs and relisting.
Revenue
Aditxt's total revenue plummeted to $748 million in Q3 2025, a sharp decline from $6,854 million in the same period last year. The entire revenue came from sales, with no additional segments contributing to the top line.
Earnings/Net Income
The company narrowed its per-share loss to $548.78 from $3.14 million in 2024 Q3, but the net loss widened to $24.21 million in 2025 Q3, representing a 246.8% increase from $6.98 million in 2024 Q3. Despite a 100% improvement in per-share losses, the company's net loss widened significantly, underscoring ongoing financial challenges.
Post-Earnings Price Action Review
The stock price of
dropped 4.90% during the latest trading day, plummeted 30.96% during the most recent full trading week, and surged 1151.15% month-to-date.Additional News
Name Change & Strategic Shift: Aditxt filed for a name change to bitXbio, Inc., aligning with its blockchain-integrated health innovation strategy.
Employee Stock Purchase Plan (ESPP): A proposed ESPP aims to align employees with shareholders, enhancing ownership culture.
Subsidiary Plans: Pearsanta, Aditxt’s precision diagnostics unit, plans an IPO in 2026, while Evofem seeks to regain a national listing and secure growth capital.
Additional News
The company’s digital asset treasury (DAT) strategy includes a crypto reserve, utility token, and tokenized ventures, though no digital assets are currently held. Pearsanta’s Mitomic® and Adductomics platforms are advancing clinical validation, while Evofem markets PHEXXI® and SOLOSEC®. Aditxt’s pivot to bitXbio reflects a broader vision to merge blockchain, public markets, and health innovation.
Image rule:
Daily Earnings
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
John Wiley Sons A 2026 Q2 Earnings EPS Surges 13.3% Despite Revenue Decline
Dec.06 2025
Petco Health 2026 Q3 Earnings Profitability Returns with 156.0% Net Income Surge
Dec.06 2025
Signet Jewelers 2026 Q3 Earnings Surpasses Expectations with 185.7% Net Income Growth
Dec.06 2025
Inotiv 2025 Q4 Earnings Narrowed Losses and 15.7% DSA Revenue Growth
Dec.06 2025
Snowflake 2026 Q3 Earnings Narrowed Losses by 11.2% as Revenue Surpasses Estimates
Dec.06 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet